This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Meridian Bioscience Establishes Direct Sales In Australia Through Bioline Australia

Stocks in this article: VIVO

Meridian Bioscience, Inc., (NASDAQ: VIVO) is pleased to announce the commencement of a new, direct distribution arrangement in Australia for the Meridian diagnostic products. Meridian is transitioning the sales of the Meridian diagnostic products from its current distributor to its direct sales force through Bioline (Aust) Pty Ltd. (Bioline Australia), a wholly-owned subsidiary of Meridian Bioscience, Inc.

Bioline Australia, The PCR Company, is a leading manufacturer and distributor of molecular biology reagents for the life science, pharmaceutical and commercial diagnostic markets. The combination of the Bioline PCR products with the Meridian portfolio of infectious disease diagnostic tests provides a unique range of products to the market. Having both product lines offered through one source will help better serve our current customers and, at the same time, increases the opportunities to reach new ones. Bioline PCR reagents complement Meridian’s new molecular platform, illumigene ®, providing a wide menu of molecular components, reagents and diagnostic tests to a broad range of laboratories.

Richard L. Eberly, Chief Commercial Officer of Meridian Bioscience, Inc., stated, “Combining our Australian business through Bioline/Meridian was a strategic decision toward strengthening our global distribution. Additionally, Bioline and Meridian have several common factors; both have innovative, high quality products which help deliver faster and more accurate results while improving patient care and both are focused on delivering strong technical support and outstanding customer service.”

Colin Denver, Regional Sales Director of Bioline Australia, stated, “We are looking forward to the opportunity to bring the Meridian infectious disease diagnostic products on board. There is a strong alignment between Meridian products and our current customer base. It is exciting to offer Meridian’s new molecular test, illumigene ®, that has a very good fit in our market.”

Bioline Australia can be reached by phone at 61(02)9209-4180, fax 61(02)9209-4763 or visit their website: www.bioline.com

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

FORWARD LOOKING STATEMENTS

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs